Dexeryl for atopic dermatitis lands in Korea

Medical device applied to the skin to treat atopic dermatitis

Dexeryl MD cream improves symptoms of various skin conditions

Pierre Fabre Korea announced that it had launched its medical device cream ‘Dexeryl’ in Korea on the 26th.

 

Dexeryl is an MD cream that represents the 60-year-old French pharmaceutical company, Pierre Fabre.

 

It is used to treat dryness of the skin and symptoms from skin conditions, such as atopic dermatitis, pruritus, diabetic foot disease, itching, psoriasis, ichthyosis, and radiodermatitis.

 

It consists of a minimum formula of 13 ingredients that excludes the 43 types of steroids, 7 types of parabens, lanolin, or odoriferous substances.

 

As an O/W(Oil in Water) formulation, it applies smoothly and has excellent moisturizing power.

 

Dexeryl, called the ‘Nation’s MD cream’ in France, recorded No.1 in sales in Europe It is currently sold in 57 countries around the globe and can be prescribed at hospitals and clinics in Korea starting at the end of November.

 

At the product launch press conference held the same day, Alain Delaurue, Global Medical Director of Pierre Fabre Group, said, “Dexeryl was developed based on our company’s extensive clinical experience and expertise, and owns clinical data on skin conditions such as atopic dermatitis published in renown journals including the Journal of the European Academy of Dermatology And Venereology (JEADV).” In a clinical trial conducted on 335 children aged 2-6 years with mild to moderate atopic dermatitis, Dexeryl lowered the frequency of acute exacerbation of atopic dermatitis and steroid use compared to the patient group that did not use moisturizers or used comparators.

 

During the clinical trial period, the rate of patients who experienced acute exacerbation more than once was 67.6% in patients who did not use MD creams, 52.6% in the control group, and 35.1% in the Dexeryl-treated group.

 

Also, the steroid use in the Dexeryl group decreased by 57.1% compared to those that did not use any MD creams.

 

Also, Dexeryl was found to be effective in treating xerosis, one of the major symptoms of atopic dermatitis.

 

In a Phase III trial on 251 children aged 2-6 years with atopic dermatitis xerosis for 28 days, The Dexeryl-treated group’s lesions from xerosis improved by 42.5%.

 

The rate was 29% for the control group.

 

Patients who discontinue the use of MD creams during the study period showed relapse, but then showed improvement in symptoms again when resuming the use of creams.

 

Also, regular use showed improvement even in a group of patients who did not respond to initial use, demonstrating the importance of long-term use of Dexeryl.

 

Hye-One Kim, Professor of Dermatology at Hallym University Kangnam Sacred Heart Hospital, said, “Patients with atopic dermatitis need to regularly use moisturizers such as MD cream twice a day because their skin barrier function is damaged, even if the symptoms are invisible.

 

Although the common perception is that MD cream is a cosmetic product due to the low awareness but for patients suffering from skin diseases, it is an important item that should be used every day like a treatment.”